Chronic myeloid leukaemia News and Research

RSS

High CIP2A may guide TKI choice for chronic phase CML

Treatment with a second-generation tyrosine kinase inhibitor prevents progression to blast crisis in chronic myeloid leukaemia patients with high levels of cancerous inhibitor of PP2A, research suggests.

29 May 2015

CML guidelines highlight need for TKI switch timing, choice

A review of the European LeukemiaNet guidelines on the care of patients with chronic myeloid leukaemia highlights the need for research into the timing and use of second-line and third-line tyrosine kinase inhibitors.

20 Apr 2015

Novel treatment strategy targets treatment-resistant CML

Researchers have shown that the coiled-coil mimetic CCmut3 can inhibit cell growth and promote apoptosis in cell lines expressing BCR–ABL1, including those resistant to tyrosine kinase inhibitors.

20 Apr 2015

Laboratory criteria for CML deep molecular response reviewed

Laboratory recommendations for the detection and measurement of a deep response to chronic myeloid leukaemia treatment have been developed as part of the European Treatment and Outcome Study for CML.

24 Mar 2015

Fourth-line bosutinib ‘appropriate’ after prior CML treatment failure, intolerance

A Spanish study suggests that bosutinib can help improve or maintain response in patients with chronic myeloid leukaemia after treatment failure of three previous tyrosine kinase inhibitors.

24 Mar 2015

TKI introduction improves French CML patient survival

Real-world study findings from France show the significant impact tyrosine kinase inhibitor treatment has had on the survival of patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

Transplantation conditioning choices impact on CML outcomes revealed

For chronic myeloid leukaemia patients in their first chronic phase, the optimal pretransplantation conditioning regimen may be cyclophosphamide combined with intravenous busulfan, research suggests.

17 Feb 2015

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

Scientists create largest ever catalogue of biological chimeras

Scientists from the Spanish National Cancer Research Centre's Structural Computational Biology Group, led by Alfonso Valencia, are making the largest ever catalogue of biological chimeras available to the public domain.

2 Feb 2015

CML mouse model reveals previously unreported facets of disease

A humanised murine model of chronic phase chronic myeloid leukaemia, developed by a Swedish research team, provides insight into previously unexplored characteristics of the disease.

12 Jan 2015

PF-114 shows promise in therapy-resistant CML, Ph-positive ALL

PF-114, a selective tyrosine kinase inhibitor, is active against native and mutated forms of the BCR–ABL oncogene in Philadelphia chromosome-positive leukaemias, according to preclinical cellular and in vivo results published in Leukemia.

12 Jan 2015

Blast phase characteristics differ in TKI-, non-TKI–treated CML patients

Features of the blast phase, such as blast cell morphology and accompanying cytogenetic changes, vary between chronic myeloid leukaemia patients who received tyrosine kinase inhibitor therapy and those treated in the pre-TKI era, research shows.

12 Jan 2015

Molecular response criteria examined for CML

The limitations in determining molecular response in patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitor therapy have been reviewed in Cancer.

9 Dec 2014

Chaetocin synergistic with TKIs against CML cells

Chaetocin, a mycotoxin that increases oxidative stress, can complement the activity of tyrosine kinase inhibitors in chronic myeloid leukaemia by overcoming innate resistance mediated by secreted bone marrow stromal cytokines and growth factors, researchers report.

14 Nov 2014

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.

27 Oct 2014

Study reveals why survival for blood cancer patients still varies between regions within Europe

Failure to get the best treatment and variations in the quality of care are the most likely reasons why survival for blood cancer patients still varies widely between regions within Europe, according to the largest population-based study of survival in European adults to date, published in The Lancet Oncology.

15 Jul 2014

Researchers investigate stickiness of leukaemia cells and its link to drug resistance

Researchers in Manchester have investigated the stickiness of leukaemia cells, and whether this is linked to drug resistance.

11 Mar 2014

Study could lead towards a personalised medicine for chemoresistant lymphomata

To date, tests have only been carried out on cells, but a piece of research conducted by the Department of Genetics at the UPV/EHU's Faculty of Medicine in collaboration with MD Anderson and the CNIO is opening up the door for the treatment of lymphoma types that have a lower survival rate. The study of the molecular characteristics of the tumours would enable molecules that are altered in a specific way to be identified and turned into new therapeutic targets that would improve the prognosis of patients with chemoresistant lymphomata.

16 Dec 2013

ARIAD Pharmaceuticals' Iclusig gets EC marketing authorization for CML and Ph+ ALL treatment

ARIAD Pharmaceuticals, Inc. today announced that the European Commission has granted a marketing authorization for Iclusig (ponatinib) as an orphan medicinal product for two indications.

2 Jul 2013

A*STAR's professor receives Szent-Gy-rgyi prize for groundbreaking cancer pill

Professor Alex Matter, Chief Executive Officer of A*STAR's Experimental Therapeutics Centre (ETC), has been awarded the 8th Annual Szent-Gy-rgyi Prize for Progress in Cancer Research by the National Foundation for Cancer Research (NFCR) for his contributions to the development of the first drug specifically targeting a molecular lesion in cancer.

7 Apr 2013